Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 976 - 1000 of 14705 in total
In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Matched Description: … and gained approval. ... has been filed with the FDA in August 2017 and FDA approved in August 2018. ... In recent years, various extended half-life factor VIII and factor IX preparations have been studied …
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic ... [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002. …
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or...
Approved
Investigational
Matched Description: … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated ... It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of ... protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
Approved
Matched Description: … Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and
Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine. Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group. To know more about the mixture please visit DB01049
Approved
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is...
Approved
Matched Iupac: … (2R,3S,4S,5S,6R)-6-{[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-{[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl- …
Matched Description: … bactericidal activity is time-dependent, and not concentration-dependent. ... the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and ... [A190492] The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the …
Matched Categories: … Alimentary Tract and Metabolism …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
Approved
Investigational
Matched Description: … It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone …
The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Description: … to treat monkeypox and cowpox in adults and children. ... [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835] ... The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, …
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Approved
Investigational
Matched Description: … Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and
A systemic agricultural fungicide and seed treatment agent.
Approved
Experimental
Matched Description: … A systemic agricultural fungicide and seed treatment agent. …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Description: … new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and
Matched Categories: … Decongestants and Antiallergics …
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Approved
Matched Description: … Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. ... water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial ... of action has not been described in the literature, though it positively modulates GABAA and
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial ... inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and
Matched Categories: … Imidazole and Triazole Derivatives …
Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate...
Approved
Matched Description: … Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. ... It is a coordination complex consisting of chromium(III) and picolinic acid. ... Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity …
Boric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes . It...
Approved
Matched Description: … It is known to exhibit some antibacterial activity against infections such as bacterial vaginosis and ... in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes ... Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive …
Propolis wax is naturally produced by honeybees by mixing the resin or exudate collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and bee enzymes. Propolis itself contains various chemical compounds including flavonoids, terpenoids, aldehydes, aromatic acids, aliphatic alcohols and ethers, amino acids,...
Approved
Matched Description: … ethers, amino acids, and sugars. ... collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and ... chemical compounds including flavonoids, terpenoids, aldehydes, aromatic acids, aliphatic alcohols and
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and
Matched Categories: … moxonidine and diuretics …
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and ... two open-label trials which showed that the onset of action was approximately 1.0 hour and the median …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Approved
Experimental
Matched Categories: … Diet, Food, and Nutrition …
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times …
Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
Approved
Matched Description: … those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and ... thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release …
Displaying drugs 976 - 1000 of 14705 in total